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Abstract The gene for a transcription factor hepatocyte nuclear
factor-4K (HNF-4K) is responsible for maturity-onset diabetes of
the young, type 1. We examined hormonal regulation of the
HNF-4K gene in the liver. Stimulation of primary-cultured rat
hepatocytes with dexamethasone or glucagon led to induction
of HNF-4K mRNA, being antagonized by insulin. In the liver of
streptozotocin-induced diabetic rat, mRNA and protein levels
for HNF-4K were elevated, and were normalized by insulin
treatment. Therefore, HNF-4K in the liver is likely to be involved
in the regulation of glucose metabolism in response to these
hormones. ß 2000 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Maturity-onset diabetes of the young (MODY) is a mono-
genic and heterogeneous form of diabetes characterized by
early-onset (usually before 25 years of age) and autosomal
dominant inheritance. Five genes have been shown or sug-
gested to be associated with di¡erent forms of MODY. These
genes include the hepatocyte nuclear factor (HNF)-4K/
MODY1 gene on chromosome 20q [1], the glucokinase/
MODY2 gene on chromosome 7p [2], the HNF-1K/MODY3
gene on chromosome 12q [3], the insulin promoter factor
(IPF)-1/MODY4 gene on chromosome 13q [4], and the
HNF-1L/MODY5 gene on chromosome 17q [5].
HNF-4K is a member of the steroid/thyroid nuclear recep-
tor superfamily of transcription factors [6], and was ¢rst iden-
ti¢ed as a factor binding to cis regulatory regions of a number
of liver selectively expressed genes [6]. In addition to the liver,
HNF-4K is expressed abundantly also in the kidney and in-
testine [6], and at lower levels in pancreatic islets and insuli-
noma cells [7]. Targeted disruption of the HNF-4K gene in
mice causes embryonic lethality associated with impaired gas-
trulation, indicating that it is essential for early development
[8]. Fatty acyl-CoA thioesters have been shown to bind HNF-
4K and modulate its transcriptional activity positively or neg-
atively, depending on the chain length and the saturation
degree of fatty acid portions [9]. Eight HNF-4K mutations
associated with MODY and late-onset diabetes have been
reported [1,10^16].
We have studied transcriptional regulation of genes for en-
zymes of the ornithine cycle [17], which is closely related to
gluconeogenesis [18,19]. Ammonia and carbon skeletons de-
rived from amino acids are converted to urea and glucose,
respectively, through the ornithine cycle and gluconeogenic
pathway in hepatocytes. The two metabolic pathways are
regulated by hormones in a coordinated manner: glucocorti-
coids and glucagon activate, while insulin represses, the genes
for enzymes of both pathways [17,20]. We demonstrated that
HNF-4K activates the gene for the second enzyme of the
ornithine cycle, named ornithine transcarbamylase, through
binding to the enhancer region of the gene [21]. On the other
hand, HNF-4K repressed the gene for the last enzyme arginase
without apparent binding to regulatory regions [22]. HNF-4K
was also reported to interact with the glucocorticoid response
unit in the promoter region of the gene for phosphoenolpyr-
uvate carboxykinase, a rate-limiting enzyme of the gluconeo-
genic pathway [23]. Therefore, HNF-4K is a candidate for the
factor involved in hormonal regulation of both urea synthesis
and gluconeogenesis. We examined whether expression of the
HNF-4K gene in the liver changes in response to hormones
controlling glucose homeostasis.
2. Materials and methods
2.1. Isolation and culture of primary hepatocytes
Parenchymal hepatocytes from male Wistar rats (140^160 g,
6 weeks) were isolated by in situ perfusion of livers with collagenase
solution as described [24,25]. Cell viability was determined by 0.2%
trypan blue exclusion and was greater than 90% in all cases. 5U106
cells were seeded into collagen-coated 10-cm dishes (Iwaki, Tokyo,
Japan) with 10 ml of Dulbecco’s modi¢ed Eagle’s medium containing
5% fetal bovine serum and 200 Wg/ml streptomycin and 100 U/ml
penicillin G.
2.2. Streptozotocin (STZ)-induced diabetic rats
Male Wistar rats (90^100 g, 5 weeks) were divided into three groups
(each containing three animals): normal control, diabetic, and insulin-
treated diabetic animals. Diabetes was induced by intraperitoneal in-
jection of STZ (100 mg/kg; Sigma, St. Louis, MO, USA) in 50 mM
citrate, pH 4.5, containing 154 mM NaCl, on two consecutive days.
Control rats were injected with the citrate bu¡er alone. Subcutaneous
injection of neutral insulin (4.0 U/kg; Novo Nordisk, Copenhagen,
Denmark) was done twice 24 and 6 h before killing on day 7. The
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 1 8 4 0 - 8
*Corresponding author. Fax: (81)-43-226 2037.
E-mail: mtak@med.m.chiba-u.ac.jp
Abbreviations: MODY, maturity-onset diabetes of the young; HNF,
hepatocyte nuclear factor; STZ, streptozotocin
FEBS 23959 21-7-00
FEBS 23959 FEBS Letters 478 (2000) 141^146
animals of all three groups were subjected to liver excision and blood
collection by cardiac puncture between 9:00 and 10:00 a.m.
Plasma glucose concentrations were measured by the mutarotase/
glucose dehydrogenase method with a glucose photometer (HemoCue
AB, Aº ngelholm, Sweden). Plasma insulin concentrations were deter-
mined by sandwich-type enzyme immunoassay using an insulin ELI-
SA kit (Morinaga, Yokohama, Japan), and plasma glucagon concen-
trations by radioimmunoassay using a Daiichi kit (Daiichi
Radioisotope Lab., Tokyo, Japan).
2.3. Northern blot analysis
Total RNA was isolated from hepatocytes and liver using the acid
guanidinium thiocyanate^phenol^chloroform extraction procedure
[26]. RNA (2 Wg/lane) was electrophoresed in denaturing formalde-
hyde^agarose (1%) gels, and blotted on nylon membranes. A digoxi-
genin-labeled antisense RNA probe was synthesized from HNF-4K
cDNA [27] (accession number D10554) under the control of the T7
promoter using a transcription kit (Roche Diagnostics, Tokyo, Ja-
pan). Hybridization followed by chemiluminescent detection on X-
ray ¢lms was done as recommended by Roche Diagnostics. Densito-
metric quanti¢cation was done using the MacBas software (Fuji Pho-
to Film, Tokyo, Japan).
2.4. Western blot analysis
Rabbit polyclonal antibody against a synthetic peptide correspond-
ing to the 11 carboxyl-terminal residues of mouse HNF-4K protein
was prepared essentially as described [6]. Protein extracts were pre-
pared from liver nuclei puri¢ed in viscous sucrose solution as de-
scribed [28]. The extracts (20 Wg of protein) were subjected to SDS^
polyacrylamide gel electrophoresis followed by electrotransfer to ni-
trocellulose membranes. Immunodetection was performed using an
ECL kit (Amersham, Little Chalfont, UK). Densitometric quanti¢ca-
tion was done using the MacBas software.
2.5. Statistical analysis
Data were expressed as means þ S.E.M. Statistical signi¢cance of
di¡erences between groups was evaluated using unpaired Student’s
t-test. When the P value was less than 0.05, the di¡erence was con-
sidered statistically signi¢cant.
3. Results
3.1. Increases in HNF-4K mRNA levels in response to
dexamethasone and glucagon in primary-cultured
hepatocytes
Rat hepatocytes were isolated by collagenase perfusion and
plated on collagen-coated dishes in a medium containing 5%
fetal bovine serum. Changes in HNF-4K mRNA levels during
the culture were monitored by Northern analysis using total
RNA prepared from the hepatocytes at various times after the
plating (Fig. 1A). HNF-4K mRNA levels decreased by 24 h
and reached a constant level, which was maintained during
the succeeding culture up to 96 h. The following experiments
were performed between 48 and 96 h of the culture.
E¡ects of glucocorticoids and glucagon on expression of the
HNF-4K gene were examined by treating the primary hepato-
cytes with these hormones separately or in combination (Fig.
1B). Hormones were added into the culture medium twice 24
and 6 h prior to harvesting the cells. A synthetic glucocorti-
coid, dexamethasone (1036 M), and glucagon (3U1038 M)
raised HNF-4K mRNA levels 5.3- and 3.5-fold, respectively.
A combination of these hormones caused an 8.9-fold increase.
Various concentrations of dexamethasone and glucagon
were tested for their e¡ects on HNF-4K mRNA levels (Fig.
2A). Dexamethasone raised HNF-4K mRNA levels in a dose-
dependent manner. The concentration for half-maximum ef-
fect (EC50) was between 1039 and 1038 M, which was con-
cordant with the Kd of 7U1039 M [29] and EC50 of 3U1039
M [30] measured with cloned glucocorticoid receptors. Gluca-
gon also raised the levels dose-dependently with EC50 of
about 10310 M, which was comparable with physiological
glucagon concentrations around 10310 M in the rat portal
vein [31] and lower than EC50 of 3.7U10310 M measured
for calcium £ux with the cloned rat glucagon receptor [32].
Time course of changes in HNF-4K mRNA levels in re-
sponse to dexamethasone or glucagon was monitored (Fig.
2B). With each hormone, increases in HNF-4K mRNA were
Fig. 1. Increases in HNF-4K mRNA levels by dexamethasone and/
or glucagon in primary-cultured rat hepatocytes. A: HNF-4K
mRNA levels in hepatocytes during the culture without hormones.
Isolated hepatocytes were plated into Dulbecco’s modi¢ed Eagle’s
medium containing 5% fetal bovine serum but no supplemented
hormones, and cultured for indicated periods. The medium was
changed at 24 and 72 h of the culture. B: Dexamethasone (1036 M,
Dex) and/or glucagon (3U1038 M, Gluc) were added into the cul-
ture medium twice, i.e. 24 h and 6 h prior to harvesting at 72 h of
the culture. Total RNA was isolated from the cells and subjected to
blot analysis for detection of HNF-4K mRNA. Representative
chemiluminograms are shown with ethidium bromide staining of
rRNAs. At the bottom of each panel, quanti¢ed results of the
chemiluminogram are presented as means þ S.E.M. for three inde-
pendent experiments.
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apparent at 6 h after addition of each hormone, reached pla-
teau levels around 24 h, and were sustained by 48 h.
3.2. Antagonistic repression by insulin of dexamethasone- or
glucagon-stimulated HNF-4K mRNA induction
E¡ects of insulin, which antagonizes glucocorticoids and
glucagon in a number of liver functions, were examined by
treating the hepatocytes with various concentrations of insulin
in combination with a ¢xed amount of dexamethasone (1036
M) or glucagon (3U1038 M) (Fig. 3). Basal HNF-4K mRNA
levels without dexamethasone nor glucagon were too low to
monitor further down-regulation by insulin, if any, quantita-
tively. HNF-4K mRNA levels raised by dexamethasone (Fig.
3A) or glucagon (Fig. 3B) were decreased by insulin dose-
Fig. 2. Characterization of increases in HNF-4K mRNA levels by dexamethasone or glucagon. A: Dose-dependency. Various concentrations of
dexamethasone (Dex) or glucagon (Gluc) were added into the culture medium of primary hepatocytes twice, i.e. 24 h and 6 h prior to harvest-
ing. B: Time course. Dexamethasone (1036 M, Dex) or glucagon (3U1038 M, Gluc) were added into the culture medium of primary hepato-
cytes at indicated times before harvesting. Total RNA was isolated from the cells and subjected to blot analysis for detection of HNF-4K
mRNA. Quanti¢ed results are presented as means þ S.E.M. for three independent experiments.
Table 1
Metabolic parameters of control, STZ-diabetic (STZ), and insulin-treated STZ-diabetic (STZ+Ins) rats
Group Body weight (g) Plasma glucose (mM) Plasma insulin (pM) Plasma glucagon (pg/ml)
Control 159.3 þ 1.2 10.4 þ 0.4 156.4 þ 34.8 215.9 þ 25.6
STZ 102.7 þ 4.69a 38.3 þ 2.9a 55.2 þ 0.6b 231.0 þ 52.0
STZ+Ins 114.3 þ 6.44 14.7 þ 1.5c 153.5 þ 36.3d 217.8 þ 36.3
Data are means þ S.E.M. of n = 3 per group. Signi¢cant di¡erences were evaluated by the Student’s t-test.
aP6 0.001 vs. control.
bP6 0.05 vs. control.
cP6 0.01 vs. STZ.
dP6 0.05 vs. STZ.
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dependently with EC50 of 1038 to 1037 M, which was some-
what higher than the maximum insulin concentration of
5U1039 M in the portal vein [31]. E¡ects of insulin against
lower and physiological concentrations of glucocorticoids and
glucagon remain to be examined.
3.3. Regulation of HNF-4K expression in the liver of the
STZ-diabetic rats
In vivo e¡ects of insulin on expression of HNF-4K were
examined by using STZ-diabetic rats. As shown in Table 1,
at day 7 after initiation of STZ treatment, the rats exhibited
diabetic pro¢les with decreased body weights, hyperglycemia
and hypoinsulinemia. Supplementation of insulin to the dia-
betic rats signi¢cantly lowered plasma glucose concentrations.
Plasma glucagon concentrations were almost constant in any
condition. HNF-4K mRNA (Fig. 4A) and protein (Fig. 4B)
were increased in livers of the STZ-diabetic rats compared to
control rats. Insulin administration normalized the increased
mRNA and protein levels completely and partially, respec-
tively, to the control levels. Therefore, expression of HNF-
4K in the liver is repressed by insulin also in vivo.
4. Discussion
In this study, we demonstrated that expression of HNF-4K
in rat hepatocytes was increased by dexamethasone and glu-
cagon, and decreased by insulin. These results suggest that
hepatic HNF-4K is involved in regulation of blood glucose
levels. A straightforward interpretation is that HNF-4K medi-
ates up-regulation of blood glucose levels in response to glu-
cocorticoids and glucagon, and down-regulation in response
to insulin. Relatively slow inductions of HNF-4K mRNA by
dexamethasone or glucagon (Fig. 2) are concordant with the
Fig. 3. Antagonistic e¡ects of insulin on dexamethasone- or gluca-
gon-stimulated increases in HNF-4K mRNA levels. Various concen-
trations of insulin in combination with dexamethasone (1036 M,
Dex) (A) or glucagon (3U1038 M, Gluc) (B) were added into the
culture medium of primary hepatocytes twice, i.e. 24 h and 6 h pri-
or to harvesting, and RNA blot analysis for HNF-4K was carried
out. Quanti¢ed results are presented as means þ S.E.M. for three in-
dependent experiments.
Fig. 4. Changes in HNF-4K mRNA (A) and protein (B) levels in
STZ diabetes with or without insulin. Livers were excised from the
normal control (Cont), STZ-diabetic (STZ), and insulin-supple-
mented STZ-diabetic (STZ+Ins) rats, each in triplicate. Total RNAs
and tissue extracts were prepared from the livers, and subjected to
Northern (A) and Western (B) analysis, respectively. Below the
Northern chemiluminogram, ethidium bromide staining of rRNAs is
shown. At the bottom of each panel, quanti¢ed results of the chemi-
luminograms are presented. Bars represent means þ S.E.M.
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notion that induced HNF-4K mediates prolonged e¡ects of
the hormones for maintenance of increased blood glucose.
However, formally, even a completely opposite interpretation
cannot be ruled out: HNF-4K rather mediates rebound from
initial e¡ects of the hormones and down-regulates blood glu-
cose levels.
HNF-4K has been reported to regulate a number of genes
involved in glucose metabolism. A study on the visceral endo-
derm developed in vitro from embryonic stem cells de¢cient in
HNF-4K revealed that this factor is critical for expression of
genes for glucose transporter 2 and glycolytic enzymes such as
aldolase B, glyceraldehyde-3-phosphate dehydrogenase and
pyruvate kinase [33]. HNF-4K binds to a DNA element of
the glucocorticoid response unit in the promoter region of
the gene for phosphoenolpyruvate carboxykinase, a key reg-
ulatory enzyme of gluconeogenesis [23], and seems to mediate
repression of the gene by fatty acyl-CoAs, the ligands of
HNF-4K [34]. Finally, the gene for another liver-enriched
transcription factor HNF-1K, which is responsible for
MODY3 [3], is under the control of HNF-4K [35]. One
MODY3 pedigree was reported to result from a mutation in
the HNF-4K-binding site in the HNF-1K gene promoter [36].
HNF-1K is expressed abundantly in endocrine pancreas [7] as
well as in hepatocytes, and implicated in transcriptional reg-
ulation of the insulin gene [37]. These observations suggest
that HNF-4K lowers blood glucose levels through stimulating
insulin synthesis and secretion in L-cells, and through inhibit-
ing gluconeogenesis and activating glucose uptake and glycol-
ysis in hepatocytes. Concordant with this notion, phosphory-
lation of HNF-4K by protein kinase A, which mediates e¡ects
of glucagon/cAMP, results in repression of DNA-binding ac-
tivity, presumably leading to attenuation of both inhibitor
and activator activities in hepatocytes in response to the hor-
mone [38].
Although previous studies [10,39] have attributed the pri-
mary defect in MODY1 mainly to L-cell failure, HNF-4K
dysfunction in the liver potentially can also contribute to ab-
normalities of glucose metabolism. While many possibilities
remain to be examined, one of the most feasible working
hypotheses for the liver-oriented etiology for MODY1 is as
follows: normal hepatic HNF-4K is a regulator lowering the
blood glucose levels by mediating the rebound from initial
e¡ects of the hormones, and mutations in the HNF-4K gene
result in derepression of genes involved in hepatic glucose
production, and/or inactivation of genes involved in hepatic
glucose utilization. To take an example for cell-di¡erential
roles of MODY genes, Postic et al. [40] recently demonstrated
that disruption of the glucokinase gene, which is responsible
for MODY2 [2], in L-cells and hepatocytes of mice led to
severe and mild hyperglycemia, respectively. Such conditional
knockout studies will be also helpful to examine cell-di¡er-
ential roles of HNF-4K.
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